DNMT2-IN-2 

DNMT2-IN-2 is a selective DNA methyltransferase 2 (DNMT2) inhibitor with a K_D value of 3.04 μM. DNMT2-IN-2 targets to a cryptic allosteric binding site of DNMT2. DNMT2-IN-2 reduces m₅C levels in MOLM-13 tRNA and synergizes with Doxorubicin (HY-15142A) to impair cell viability. DNMT2-IN-2 can be used for cancer research, such as cervical cancer and leukemia^[1].

DNMT2-IN-2 (Compound 16) (50 μM, 72 h) significantly reduces levels of targeted tRNA modifications (m₅C and m₅Cm) in MOLM-13 cells^[1].
DNMT2-IN-2 (50 μM, 16 h) shows thermal stabilization of DNMT2 in MOLM-13 cells^[1].
DNMT2-IN-2 (1-100 μM, 48 h) shows low toxicity in HCT 116, MOLM13, HEK293, MOLM-13 and Huh7 cells^[1].
DNMT2-IN-2 (50 μM, 6 days) makes cells more susceptible to Doxorubicin (HY-15142A) in MOLM-13, Huh-7 and MDA-MB-231 cells^[1].
DNMT2-IN-2 (50 μM, 45 mins) does not display NonO nor eIF4E from binding to immobilized DNMT2^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

499.00

C₂₆H₃₁ClN₄O₄

NC(CNC(C[C@H](NC(C1(CC1)CNC(C2=CC(CC)=CC=C2)=O)=O)CC3=CC=C(C=C3)Cl)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Frey AF, et al. DNA-encoded library screening uncovers potent DNMT2 inhibitors targeting a cryptic allosteric binding site. iScience. 2025 Aug 5;28(9):113300.